Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?

Anahid Hamparsumian,Colette Whitney,Dan Blalock,Andrea Sitlinger,Mohammad Shahsahebi,Kevin Oeffinger,Leah Zullig,Danielle Brander

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览4

暂无评分

摘要

Over two-thirds (65%) of CLL/SLL patients developed new-onset or uncontrolled hypertension after starting ibrutinib. Age did not appear to be associated with these changes. The increase in prevalence of hypertension highlights the importance of blood pressure monitoring, irrespective of age, after initiation of ibrutinib.

查看译文

关键词

CLL,hypertension,blood pressure,ibrutinib,age

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要